Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis

Benjamin Gelman, Joshua G. Lisinicchia, Tianshen Chen, Kenneth M. Johnson, Kristofer Jennings, Daniel H. Freeman, Vicki M. Soukup

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Changes in synapse structure occur in frontal neocortex with HIVencephalitis (HIVE) and may contribute to HIV-associated neurocognitive disorders (HAND). A postmortem survey was conducted to determine if mRNAs involved in synaptic transmission are perturbed in dorsolateral prefrontal cortex (DLPFC) in subjects with HIVE or HAND. Expression of the opioid neurotransmitter preproenkephalin mRNA (PENK) was significantly decreased in a sampling of 446 brain specimens from HIV-1 infected people compared to 67 HIV negative subjects. Decreased DLPFC PENK was most evident in subjects with HIVE and/or increased expression of interferon regulatory factor 1 mRNA (IRF1). Type 2 dopamine receptor mRNA (DRD2L) was decreased significantly, but not in the same set of subjects with PENK dysregulation. DRD2L downregulation occurred primarily in the subjects without HIVE or neurocognitive impairment. Subjects with neurocognitive impairment often failed to significantly downregulate DRD2L and had abnormally high IRF1 expression. Conclusion: Dysregulation of synaptic preproenkephalin and DRD2L in frontal neocortex can occur with and without neurocognitive impairment in HIV-infected people. Downregulation of DRD2L in the prefrontal cortex was associated with more favorable neuropsychological and neuropathological outcomes; the failure to downregulate DRD2L was significantly less favorable. PENK downregulation was related neuropathologically to HIVE, but was not related to neuropsychological outcome independently. Emulating endogenous synaptic plasticity pharmacodynamically could enhance synaptic accommodation and improve neuropsychological and neuropathological outcomes in HIV/AIDS.

Original languageEnglish (US)
Pages (from-to)686-700
Number of pages15
JournalJournal of NeuroImmune Pharmacology
Volume7
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Encephalitis
HIV
Messenger RNA
Down-Regulation
Prefrontal Cortex
Interferon Regulatory Factor-1
Neocortex
Neuronal Plasticity
Neurocognitive Disorders
Dopamine Receptors
Synaptic Transmission
Synapses
Opioid Analgesics
Neurotransmitter Agents
HIV-1
Acquired Immunodeficiency Syndrome
preproenkephalin
Brain

Keywords

  • Dopamine receptor
  • Enkephalin
  • HAND
  • HIV-associated neurocognitive disorders
  • HIVE
  • HIVencephalitis
  • Interferon regulatory factor
  • Opiate
  • Opioid
  • Synaptic plasticity

ASJC Scopus subject areas

  • Pharmacology
  • Immunology and Allergy
  • Immunology
  • Neuroscience (miscellaneous)

Cite this

Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. / Gelman, Benjamin; Lisinicchia, Joshua G.; Chen, Tianshen; Johnson, Kenneth M.; Jennings, Kristofer; Freeman, Daniel H.; Soukup, Vicki M.

In: Journal of NeuroImmune Pharmacology, Vol. 7, No. 3, 09.2012, p. 686-700.

Research output: Contribution to journalArticle

Gelman, Benjamin ; Lisinicchia, Joshua G. ; Chen, Tianshen ; Johnson, Kenneth M. ; Jennings, Kristofer ; Freeman, Daniel H. ; Soukup, Vicki M. / Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. In: Journal of NeuroImmune Pharmacology. 2012 ; Vol. 7, No. 3. pp. 686-700.
@article{3bfccb2a2cbd4b4a9624ab95347cbeba,
title = "Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis",
abstract = "Changes in synapse structure occur in frontal neocortex with HIVencephalitis (HIVE) and may contribute to HIV-associated neurocognitive disorders (HAND). A postmortem survey was conducted to determine if mRNAs involved in synaptic transmission are perturbed in dorsolateral prefrontal cortex (DLPFC) in subjects with HIVE or HAND. Expression of the opioid neurotransmitter preproenkephalin mRNA (PENK) was significantly decreased in a sampling of 446 brain specimens from HIV-1 infected people compared to 67 HIV negative subjects. Decreased DLPFC PENK was most evident in subjects with HIVE and/or increased expression of interferon regulatory factor 1 mRNA (IRF1). Type 2 dopamine receptor mRNA (DRD2L) was decreased significantly, but not in the same set of subjects with PENK dysregulation. DRD2L downregulation occurred primarily in the subjects without HIVE or neurocognitive impairment. Subjects with neurocognitive impairment often failed to significantly downregulate DRD2L and had abnormally high IRF1 expression. Conclusion: Dysregulation of synaptic preproenkephalin and DRD2L in frontal neocortex can occur with and without neurocognitive impairment in HIV-infected people. Downregulation of DRD2L in the prefrontal cortex was associated with more favorable neuropsychological and neuropathological outcomes; the failure to downregulate DRD2L was significantly less favorable. PENK downregulation was related neuropathologically to HIVE, but was not related to neuropsychological outcome independently. Emulating endogenous synaptic plasticity pharmacodynamically could enhance synaptic accommodation and improve neuropsychological and neuropathological outcomes in HIV/AIDS.",
keywords = "Dopamine receptor, Enkephalin, HAND, HIV-associated neurocognitive disorders, HIVE, HIVencephalitis, Interferon regulatory factor, Opiate, Opioid, Synaptic plasticity",
author = "Benjamin Gelman and Lisinicchia, {Joshua G.} and Tianshen Chen and Johnson, {Kenneth M.} and Kristofer Jennings and Freeman, {Daniel H.} and Soukup, {Vicki M.}",
year = "2012",
month = "9",
doi = "10.1007/s11481-012-9345-4",
language = "English (US)",
volume = "7",
pages = "686--700",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis

AU - Gelman, Benjamin

AU - Lisinicchia, Joshua G.

AU - Chen, Tianshen

AU - Johnson, Kenneth M.

AU - Jennings, Kristofer

AU - Freeman, Daniel H.

AU - Soukup, Vicki M.

PY - 2012/9

Y1 - 2012/9

N2 - Changes in synapse structure occur in frontal neocortex with HIVencephalitis (HIVE) and may contribute to HIV-associated neurocognitive disorders (HAND). A postmortem survey was conducted to determine if mRNAs involved in synaptic transmission are perturbed in dorsolateral prefrontal cortex (DLPFC) in subjects with HIVE or HAND. Expression of the opioid neurotransmitter preproenkephalin mRNA (PENK) was significantly decreased in a sampling of 446 brain specimens from HIV-1 infected people compared to 67 HIV negative subjects. Decreased DLPFC PENK was most evident in subjects with HIVE and/or increased expression of interferon regulatory factor 1 mRNA (IRF1). Type 2 dopamine receptor mRNA (DRD2L) was decreased significantly, but not in the same set of subjects with PENK dysregulation. DRD2L downregulation occurred primarily in the subjects without HIVE or neurocognitive impairment. Subjects with neurocognitive impairment often failed to significantly downregulate DRD2L and had abnormally high IRF1 expression. Conclusion: Dysregulation of synaptic preproenkephalin and DRD2L in frontal neocortex can occur with and without neurocognitive impairment in HIV-infected people. Downregulation of DRD2L in the prefrontal cortex was associated with more favorable neuropsychological and neuropathological outcomes; the failure to downregulate DRD2L was significantly less favorable. PENK downregulation was related neuropathologically to HIVE, but was not related to neuropsychological outcome independently. Emulating endogenous synaptic plasticity pharmacodynamically could enhance synaptic accommodation and improve neuropsychological and neuropathological outcomes in HIV/AIDS.

AB - Changes in synapse structure occur in frontal neocortex with HIVencephalitis (HIVE) and may contribute to HIV-associated neurocognitive disorders (HAND). A postmortem survey was conducted to determine if mRNAs involved in synaptic transmission are perturbed in dorsolateral prefrontal cortex (DLPFC) in subjects with HIVE or HAND. Expression of the opioid neurotransmitter preproenkephalin mRNA (PENK) was significantly decreased in a sampling of 446 brain specimens from HIV-1 infected people compared to 67 HIV negative subjects. Decreased DLPFC PENK was most evident in subjects with HIVE and/or increased expression of interferon regulatory factor 1 mRNA (IRF1). Type 2 dopamine receptor mRNA (DRD2L) was decreased significantly, but not in the same set of subjects with PENK dysregulation. DRD2L downregulation occurred primarily in the subjects without HIVE or neurocognitive impairment. Subjects with neurocognitive impairment often failed to significantly downregulate DRD2L and had abnormally high IRF1 expression. Conclusion: Dysregulation of synaptic preproenkephalin and DRD2L in frontal neocortex can occur with and without neurocognitive impairment in HIV-infected people. Downregulation of DRD2L in the prefrontal cortex was associated with more favorable neuropsychological and neuropathological outcomes; the failure to downregulate DRD2L was significantly less favorable. PENK downregulation was related neuropathologically to HIVE, but was not related to neuropsychological outcome independently. Emulating endogenous synaptic plasticity pharmacodynamically could enhance synaptic accommodation and improve neuropsychological and neuropathological outcomes in HIV/AIDS.

KW - Dopamine receptor

KW - Enkephalin

KW - HAND

KW - HIV-associated neurocognitive disorders

KW - HIVE

KW - HIVencephalitis

KW - Interferon regulatory factor

KW - Opiate

KW - Opioid

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=84866096031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866096031&partnerID=8YFLogxK

U2 - 10.1007/s11481-012-9345-4

DO - 10.1007/s11481-012-9345-4

M3 - Article

C2 - 22391864

AN - SCOPUS:84866096031

VL - 7

SP - 686

EP - 700

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 3

ER -